Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Adverum Biotechnologies, Inc.

Get SEC filing alerts via email and in your feed for Adverum Biotechnologies, Inc.

ADVM

Adverum Biotechnologies, Inc.

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies is a clinical-stage biopharmaceutical company focused on developing gene therapies for prevalent ocular diseases, primarily wet age-related macular degeneration (wet AMD). Its lead product, Ixo-vec, is a single intravitreal injection gene therapy designed to provide sustained delivery of aflibercept, reducing treatment burden and improving vision outcomes. Adverum leverages proprietary AAV vector technology, scalable manufacturing, and clinical expertise to address unmet needs in ophthalmology.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Adverum Biotechnologies, Inc.

1
1
Adverum Biotechnologies, Inc. Adverum Biotechnologies Reports $47.7 Million Net Loss and Plans Merger with Eli Lilly

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Adverum Biotechnologies, Inc. Adverum Biotechnologies Reports $49.2 Million Net Loss and Financial Challenges in Latest Filing

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Adverum Biotechnologies, Inc. Adverum Biotechnologies Reports $47M Net Loss and Financial Challenges in Latest 10-Q

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Adverum Biotechnologies, Inc. Adverum Biotechnologies Reports $130.9 Million Net Loss for 2024, License Revenue Declines

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Adverum Biotechnologies, Inc. Adverum Biotechnologies Reports Improved Financial Performance, Cash Reserves, and Progress on Lead Product Candidate Ixo-vec

Via official filing (AI summary) | over 1 year ago | 0 comments